AR114828A1 - Compuestos de pteridinona y sus usos - Google Patents
Compuestos de pteridinona y sus usosInfo
- Publication number
- AR114828A1 AR114828A1 ARP190101061A ARP190101061A AR114828A1 AR 114828 A1 AR114828 A1 AR 114828A1 AR P190101061 A ARP190101061 A AR P190101061A AR P190101061 A ARP190101061 A AR P190101061A AR 114828 A1 AR114828 A1 AR 114828A1
- Authority
- AR
- Argentina
- Prior art keywords
- nitrogen
- oxygen
- sulfur
- partially unsaturated
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661744P | 2018-04-24 | 2018-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114828A1 true AR114828A1 (es) | 2020-10-21 |
Family
ID=66655428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101061A AR114828A1 (es) | 2018-04-24 | 2019-04-23 | Compuestos de pteridinona y sus usos |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11059826B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3784669B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7479293B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112218865B (cg-RX-API-DMAC7.html) |
| AR (1) | AR114828A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019257651B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3097774A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2969982T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL278122B2 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI884914B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019209757A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3784669B1 (en) | 2018-04-24 | 2023-10-25 | Vertex Pharmaceuticals Incorporated | Pteridinone compounds and uses thereof |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| US12617784B2 (en) | 2019-01-29 | 2026-05-05 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | AKT inhibitor |
| AU2020368368B2 (en) * | 2019-10-14 | 2026-03-19 | The Regents Of The University Of California | Broad spectrum anti-cancer compounds |
| WO2022023339A1 (en) | 2020-07-29 | 2022-02-03 | Bayer Aktiengesellschaft | Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof |
| EP4238974A4 (en) * | 2020-10-28 | 2024-10-23 | Adlai Nortye Biopharma Co., Ltd. | HIGH ACTIVITY WNT PATHWAY INHIBITOR COMPOUND |
| TW202334157A (zh) * | 2022-01-29 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Wnt通路抑制劑化合物 |
| TW202333697A (zh) * | 2022-01-30 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | Wnt通路抑制劑化合物 |
| CN114436918B (zh) * | 2022-02-23 | 2023-05-23 | 郑州大学 | 环丁-1-烯胺类化合物及其制备方法和在药物中的应用 |
| WO2024022365A1 (zh) * | 2022-07-28 | 2024-02-01 | 杭州阿诺生物医药科技有限公司 | 一种Wnt通路抑制剂化合物 |
| US20240217951A1 (en) * | 2022-09-23 | 2024-07-04 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| US6806272B2 (en) * | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| UY27427A1 (es) | 2001-09-04 | 2003-03-31 | Boehringer Ingelheim Pharma | Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
| WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| AU2011226830A1 (en) * | 2004-08-14 | 2011-10-13 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| WO2007014838A1 (en) * | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Dihydropteridinones in the treatment of respiratory diseases |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체 |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US8865716B2 (en) | 2012-02-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Dihydropteridinones II |
| EP2958919B1 (en) | 2013-02-21 | 2019-05-22 | Boehringer Ingelheim International GmbH | Dihydropteridinones i |
| JP6072308B2 (ja) | 2013-02-21 | 2017-02-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノンii |
| KR20160111520A (ko) | 2014-01-31 | 2016-09-26 | 다나-파버 캔서 인스티튜트 인크. | 디히드로프테리디논 유도체 및 그의 용도 |
| WO2015193229A1 (de) | 2014-06-19 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe |
| CA2986441A1 (en) * | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CN105801582A (zh) * | 2016-04-12 | 2016-07-27 | 合肥工业大学 | 一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途 |
| EP3784669B1 (en) * | 2018-04-24 | 2023-10-25 | Vertex Pharmaceuticals Incorporated | Pteridinone compounds and uses thereof |
-
2019
- 2019-04-23 EP EP19726791.7A patent/EP3784669B1/en active Active
- 2019-04-23 JP JP2020559365A patent/JP7479293B2/ja active Active
- 2019-04-23 WO PCT/US2019/028604 patent/WO2019209757A1/en not_active Ceased
- 2019-04-23 AU AU2019257651A patent/AU2019257651B2/en active Active
- 2019-04-23 AR ARP190101061A patent/AR114828A1/es unknown
- 2019-04-23 ES ES19726791T patent/ES2969982T3/es active Active
- 2019-04-23 CN CN201980035546.1A patent/CN112218865B/zh active Active
- 2019-04-23 US US16/391,407 patent/US11059826B2/en active Active
- 2019-04-23 CA CA3097774A patent/CA3097774A1/en active Pending
- 2019-04-23 TW TW108114117A patent/TWI884914B/zh active
- 2019-04-23 IL IL278122A patent/IL278122B2/en unknown
-
2021
- 2021-03-01 US US17/188,132 patent/US11572364B2/en active Active
-
2022
- 2022-12-05 US US18/075,270 patent/US12384790B2/en active Active
-
2023
- 2023-06-15 JP JP2023098522A patent/JP2023116712A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202010744A (zh) | 2020-03-16 |
| JP7479293B2 (ja) | 2024-05-08 |
| EP3784669A1 (en) | 2021-03-03 |
| CN112218865B (zh) | 2024-03-12 |
| TWI884914B (zh) | 2025-06-01 |
| US20230312587A1 (en) | 2023-10-05 |
| IL278122B1 (en) | 2023-09-01 |
| US12384790B2 (en) | 2025-08-12 |
| US11059826B2 (en) | 2021-07-13 |
| CN112218865A (zh) | 2021-01-12 |
| US20220363685A1 (en) | 2022-11-17 |
| IL278122A (en) | 2020-11-30 |
| AU2019257651A1 (en) | 2020-10-15 |
| WO2019209757A1 (en) | 2019-10-31 |
| US11572364B2 (en) | 2023-02-07 |
| JP2021522237A (ja) | 2021-08-30 |
| EP3784669B1 (en) | 2023-10-25 |
| ES2969982T3 (es) | 2024-05-23 |
| AU2019257651B2 (en) | 2023-05-25 |
| IL278122B2 (en) | 2024-01-01 |
| CA3097774A1 (en) | 2019-10-31 |
| JP2023116712A (ja) | 2023-08-22 |
| US20190322673A1 (en) | 2019-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| AR104789A1 (es) | Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste | |
| AR110405A1 (es) | Compuestos | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR098721A1 (es) | Inhibidores de biarilo de tirosina quinasa de bruton | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR108011A1 (es) | Moduladores receptores de estrógenos | |
| AR111983A1 (es) | ANILLOS 6 - 5 FUSIONADOS COMO INHIBIDORES DE C5a | |
| AR116114A1 (es) | Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR114496A1 (es) | Compuestos antiproliferación y usos de los mismos | |
| AR101561A1 (es) | Nucleósidos de 2-cloro aminopirimidinona y pirimidina diona | |
| AR108387A1 (es) | Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor | |
| AR108899A1 (es) | Compuesto derivado heterocíclico y su utilización | |
| AR110238A1 (es) | Derivado de pirido[3,4-d]pirimidina y su sal farmacéuticamente aceptable | |
| AR088565A1 (es) | Inhibidor de cetp de oxazolidinona biciclico fusionado | |
| AR102258A1 (es) | Compuestos de quinolina y quinazolina | |
| AR120452A1 (es) | Compuestos heterocíclicos y usos de los mismos | |
| AR098436A1 (es) | Compuestos tricíclicos de piperidina | |
| PE20190803A1 (es) | 1-arilnaftiridin-3-carboxamidas 7-sustituidas y su uso | |
| AR109588A1 (es) | Compuestos reguladores del crecimiento vegetal | |
| AR125365A1 (es) | Derivados de 1h-pirazol como ligandos sigma | |
| AR100732A1 (es) | Derivados aminoéster sustituidos con quinuclidina | |
| AR111826A1 (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias |